Our data indicated that MKI-2 can increase PP2A activity and decrease c-Myc proteins (Figure 3A,B), suggesting that MKI-2 inhibits the MASTL-PP2A-c-Myc axis in breast cancer cells. This evidence concerns the gene PTPA and breast carcinoma.